SCHEMBL20156304

SCHEMBL20156304

COC(=O)c1ccn(CCC2(C)OCCO2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.47
POLB P06746 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
RAB9A P51151 6/20 0.47
NPC1 O15118 5/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 3/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KDM4C Q9H3R0 1/20 0.35
AR P10275 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TSHR P16473 1/20 0.33
MAPT P10636 1/20 0.33
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
NR5A2 O00482 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20139139 0.81 MGAM (0.39) ALDH1A1SMN1; SMN2HPGDGAA
SCHEMBL20139822 0.80 ALDH1A1 (0.38) KMT2APOLBTDP1RAB9ANPC1
SCHEMBL20139419 0.78 KCNA5 (0.33) KMT2APOLBTDP1RAB9ANPC1
SCHEMBL21281676 0.78 ADRB3 (0.40) KMT2APOLBTDP1SMN1; SMN2
SCHEMBL20156306 0.76 RAB9A (0.55) KMT2APOLBTDP1RAB9ANPC1
SCHEMBL20139123 0.75 KCNH2 (0.39) KMT2AMEN1
SCHEMBL25786633 0.75 RAB9A (0.57) KMT2APOLBTDP1RAB9ANPC1
SCHEMBL28851114 0.75 NPC1 (0.53) KMT2APOLBTDP1RAB9ANPC1
SCHEMBL20139105 0.74 MAPT (0.51) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL20156354 0.74 F2 (0.39) KMT2ARAB9ANPC1MEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3538527-B1 AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-10-13 EP disclosed
US-10851098-B2 Azole amides and amines as alpha v integrin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-12-01 US disclosed
US-20190256513-A1 AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-08-22 US disclosed
WO-2018089358-A1 AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851098-B2 Azole amides and amines as alpha v integrin inhibitors ITGAV, ITGB1, ITGA1 KMT2A 2129/4885POLB 4152/4885TDP1 4266/4885
US-20190256513-A1 AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS ITGAV, ITGB1, ITGA1 KMT2A 2129/4885POLB 4152/4885TDP1 4266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.